Skin Irritation Potential of MOB015B in Healthy Subjects Using a Cumulative Irritant Patch Test Design
Conditions: Erythema Interventions: Drug: MOB015B; Drug: 0.2% SLS; Drug: 0.9% Saline; Drug: MOB015B vehicle Sponsors: Moberg Pharma AB Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 17, 2024 Category: Research Source Type: clinical trials
Arrivo Bio Initiates Large Phase 2b Clinical Trial in Major Depressive Disorder with Novel SIRT6 Activator SP-624
MORRISVILLE, N.C.--(BUSINESS WIRE) April 16, 2024 -- Arrivo BioVentures announced today a significant step forward in the fight against major depressive disorder (MDD) with the dosing of the first patient in the SP-624-202 clinical trial.
This... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 16, 2024 Category: Pharmaceuticals Source Type: clinical trials
TLX101-CDx (Pixclara) Granted FDA Fast Track Designation
Melbourne (Australia) | 16 April 2024 -- Telix today announces that the United States (U.S.) Food and Drug Administration (FDA) has granted Fast Track designation1 for the Company’s investigational glioma imaging product, TLX101-CDx... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 16, 2024 Category: Pharmaceuticals Source Type: clinical trials
The United States FDA Awards Orphan Drug Designation (ODD) to NM5072 for Treating Paroxysmal Nocturnal Hemoglobinuria (PNH)
CLEVELAND, April 15, 2024 (GLOBE NEWSWIRE) -- NovelMed today announced that the Food and Drug Administration (FDA) has awarded Orphan Drug Designation (ODD) to NM5072, an Alternative Pathway (AP) blocker anti-Properdin antibody, for the... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 15, 2024 Category: Pharmaceuticals Source Type: clinical trials
Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer
Conditions: Triple Negative Breast Neoplasms Interventions: Drug: Abemaciclib; Drug: Bicalutamide Sponsors: Universitaire Ziekenhuizen KU Leuven; Kom Op Tegen Kanker; Eli Lilly and Company; Teva Pharma Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
ALS Phase II Study of NX210c
Conditions: Amyotrophic Lateral Sclerosis Interventions: Drug: NX210c; Drug: Placebo Sponsors: Axoltis Pharma; ACT4ALS network Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors
Conditions: Solid Tumor Interventions: Drug: ASP4396 Sponsors: Astellas Pharma Inc Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Conditions: Advanced Cancer; Advanced Solid Tumor; Melanoma; Metastasis; Pleural Mesothelioma; Renal Cell Carcinoma; MSI-High; Mismatch Repair Deficiency; Colorectal Cancer; Hepatocellular Carcinoma; Hepatocellular Cancer; Renal Cell Cancer; Kidney Cancer; Skin Cancer; Non Small Cell Lung Cancer; NSCLC; Anaplastic Lymphoma Kinase Genomic Tumor Aberrations; ALK Genomic Tumor Aberrations Interventions: Drug: Alintegimod; Drug: Ipilimumab; Drug: Nivolumab Sponsors: 7 Hills Pharma, LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2024 Category: Research Source Type: clinical trials
A Global Phase 3 Study of Orelabrutinib+BR vs.BR in Pts With TN MCL
Conditions: Mantle Cell Lymphoma Interventions: Drug: Orelabrutinib; Drug: Bendamustine Injection; Drug: Rituximab; Drug: Orelabrutinib Placebo Sponsors: InnoCare Pharma Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2024 Category: Research Source Type: clinical trials
PaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA Submission
TARRYTOWN, New York, April 11, 2024– via IBN– PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced the completed execution of its three pivotal... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 11, 2024 Category: Pharmaceuticals Source Type: clinical trials
Interventional, Monocentric, Double-blind Randomized Category 2b Study Evaluating the Evaluation of the Tolerance of Cyto-selective Difluoroethane-based Cryotherapy in the Treatment of Brown Spots (Solar and Senile Lentigines, Post -Inflammatory Hyperpigmentation (Pih)) on the Face
Conditions: Lentigo; Solar Lentigo; Post Inflammatory Hyperpigmentation Interventions: Device: CRYONOVE (EC14_4osc); Device: CRYONOVE (EC05osc) Sponsors: Cryonove Pharma; Dermatech Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 11, 2024 Category: Research Source Type: clinical trials
A First-in-human Trial to Evaluate Safety, Tolerability, and Pharmacokinetics of APC148 in Healthy Adults
Conditions: Healthy Subjects Interventions: Drug: APC148 and Placebo Sponsors: AdjuTec Pharma AS; CTC Clinical Trial Consultants AB Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 11, 2024 Category: Research Source Type: clinical trials
Study Reveals No Causal Link Between Neurodevelopmental Disorders and Acetaminophen Exposure Before Birth
April 11, 2024 -- Study reveals no causal link between neurodevelopmental disorders and acetaminophen exposure before birth. NIH-funded research in siblings finds previously reported connection is likely due to other underlying... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 11, 2024 Category: Pharmaceuticals Source Type: clinical trials
AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
OCALA, Fla., April 10, 2024— AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced top-line interim data indicating that combining Ampligen (rintatolimod) with Keytruda (pembrolizumab) in the treatment of recurrent... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 10, 2024 Category: Pharmaceuticals Source Type: clinical trials
Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome
CAMBRIDGE, Mass.--(BUSINESS WIRE) April 10, 2024 -- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the“Company”) today announced interim data from the ongoing Phase 2 HELIOS clinical trial of AMX0035 (sodium... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 10, 2024 Category: Pharmaceuticals Source Type: clinical trials
